Skip to main content

Black Men More Likely Than Whites to Have Prostate Cancer at Any Given PSA Level

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 6, 2023.

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 6, 2023 -- At any given prostate-specific antigen (PSA) level, Black men are more likely than White men to develop prostate cancer, according to a study published online Nov. 6 in Cancer.

Kyung Min Lee, Ph.D., from the VA Salt Lake City Health Care System, and colleagues predicted the likelihood of prostate cancer diagnosis on first biopsy for 75,295 Black and 207,658 White male veterans in multivariable logistic regression models that included self‐identified race, age at first PSA test, prebiopsy PSA, age at first biopsy, smoking status, statin use, and socioeconomic factors.

The researchers found that Black veterans were 50 percent more likely to receive a prostate cancer diagnosis on their first prostate biopsy than White veterans after controlling for PSA and other covariates (odds ratio, 1.50). The probability of prostate cancer was 49 and 39 percent for a Black man and White man, respectively, at a PSA level of 4.0 ng/mL. The risk for prostate cancer was equivalent for Black veterans with a PSA of 4.0 ng/mL and White veterans with a PSA of 13.4 ng/mL.

"Combined with population‐level data suggesting both earlier onset and higher incidence of prostate cancer in Black men, our findings may indicate a need for PSA biopsy thresholds to be informed by a better understanding of patient risk factors," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.